Protalix Non Currrent Assets Other vs Total Current Assets Analysis
PLX Stock | USD 1.20 0.06 5.26% |
Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Non Currrent Assets Other and its Total Current Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
Non Currrent Assets Other vs Total Current Assets
Non Currrent Assets Other vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Non Currrent Assets Other account and Total Current Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Protalix Biotherapeutics' Non Currrent Assets Other and Total Current Assets is -0.27. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Non Currrent Assets Other and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Protalix Biotherapeutics are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Non Currrent Assets Other i.e., Protalix Biotherapeutics' Non Currrent Assets Other and Total Current Assets go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 24.9 M in 2024, despite the fact that Selling General Administrative is likely to grow to (24.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 38.4M | 47.6M | 65.5M | 68.8M | Depreciation And Amortization | 401K | 2.2M | 1.2M | 1.7M |
Protalix Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Protalix Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protalix Biotherapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 45.4M | 67.9M | 73.7M | 55.8M | 84.4M | 51.0M | |
Other Current Liab | 11.9M | 13.9M | 16.4M | 12.3M | 16.7M | 17.5M | |
Total Current Liabilities | 40.2M | 86.5M | 33.2M | 32.4M | 45.5M | 47.8M | |
Net Debt | 43.1M | 46.1M | (5.5M) | 16.4M | 2.6M | 2.8M | |
Cash | 17.8M | 18.3M | 39.0M | 17.1M | 23.6M | 31.8M | |
Non Current Assets Total | 12.9M | 12.2M | 12.0M | 10.9M | 14.5M | 9.6M | |
Cash And Short Term Investments | 17.8M | 38.5M | 39.0M | 22.2M | 44.6M | 33.7M | |
Net Receivables | 4.7M | 2M | 3.4M | 4.6M | 5.3M | 3.1M | |
Common Stock Shares Outstanding | 14.8M | 29.1M | 44.1M | 48.5M | 82.4M | 86.5M | |
Liabilities And Stockholders Equity | 45.4M | 67.9M | 73.7M | 55.8M | 84.4M | 51.0M | |
Non Current Liabilities Total | 75.5M | 8.5M | 46.5M | 34.0M | 5.3M | 5.1M | |
Other Current Assets | 698K | 2.1M | 1.3M | 536K | 1.1M | 1.6M | |
Total Liab | 115.7M | 95.0M | 79.7M | 66.4M | 50.9M | 56.1M | |
Total Current Assets | 32.5M | 55.7M | 61.7M | 44.9M | 69.9M | 42.5M | |
Short Long Term Debt Total | 60.9M | 64.4M | 33.5M | 33.5M | 26.3M | 51.0M | |
Total Stockholder Equity | (70.3M) | (27.0M) | (6.0M) | (10.6M) | 33.6M | 35.2M | |
Property Plant And Equipment Net | 11.0M | 10.4M | 9.9M | 9.6M | 10.9M | 10.5M | |
Retained Earnings | (340.8M) | (347.4M) | (374.9M) | (389.9M) | (381.5M) | (362.5M) | |
Non Currrent Assets Other | 2.0M | 1.8M | 2.1M | 1.3M | 528.0K | 501.6K | |
Common Stock Total Equity | 144K | 148K | 15K | 35K | 40.3K | 62.7K | |
Other Stockholder Equity | 270.5M | 320.3M | 368.9M | 379.2M | 415.0M | 435.8M | |
Short Term Debt | 5.4M | 59.9M | 1.2M | 1.1M | 21.7M | 18.4M | |
Common Stock | 15K | 35K | 46K | 54K | 73K | 62.8K | |
Accounts Payable | 6.5M | 7.2M | 7.0M | 5.9M | 4.3M | 4.3M | |
Short Term Investments | 26K | 20.3M | 39.0M | 5.1M | 20.9M | 22.0M | |
Other Assets | 2.0M | 7.4K | 2.1M | 1.3M | 1.0 | 0.95 | |
Other Liab | 20.1M | 4.0M | 14.3M | 1.6M | 1.5M | 1.4M | |
Property Plant Equipment | 5.3M | 10.4M | 9.9M | 9.6M | 8.7M | 8.1M | |
Current Deferred Revenue | 16.3M | 5.4M | 8.6M | 13.2M | 2.9M | 2.7M | |
Inventory | 8.2M | 13.1M | 18.0M | 16.8M | 19.0M | 9.6M | |
Net Tangible Assets | (70.3M) | (27.0M) | (6.0M) | (10.6M) | (9.6M) | (10.1M) | |
Long Term Debt | 51.0M | 51K | 27.9M | 28.2M | 25.4M | 28.8M | |
Capital Surpluse | 270.5M | 320.3M | 368.9M | 379.2M | 436.0M | 272.0M | |
Non Current Liabilities Other | 5.1M | 5.3M | 75.5M | 51K | 45.9K | 43.6K | |
Long Term Debt Total | 51.5M | 51K | 27.9M | 28.2M | 25.4M | 28.3M | |
Net Invested Capital | (15.1M) | 31.5M | 21.9M | 17.5M | 53.8M | 56.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Global Correlations Find global opportunities by holding instruments from different markets |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.08 | Revenue Per Share 0.835 | Quarterly Revenue Growth (0.61) | Return On Assets 0.0645 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.